|Videos|June 23, 2023
Generational Perspective in Multiple Sclerosis Care
Dr Krieger, Dr Brandstadter, and Dr Lublin discuss the advances made in recognizing and managing multiple sclerosis over the last few decades and the challenges that remain.
Advertisement
Episodes in this series
2:00 MS as a previously untreatable disease and evolution of DMTs
5:49 Progress in treating MS
8:18 Anti-CD20 B-cell therapies in MS
10:48 CNS agents to treat MS
12:00 Evolution of risk assessment in MS
16:38 Escalation vs high efficacy approach in MS
22:40 Disease activity/progression in MS
26:59 Progression independent of relapse in MS
28:30 Patient reported outcomes and shared decision making
34:04 MS care in older patients
Advertisement
Related to this article
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
2
Advances in Spinal Cord MRI for Multiple Sclerosis: Julien Cohen-Adad, PhD
3
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5